A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes. Reumatismo, [S. l.], 2025. DOI: 10.4081/reumatismo.2025.1748. Disponível em: https://www.reumatismo.org/reuma/article/view/1748. Acesso em: 4 aug. 2025.